PA
DNA icon

PharVision Advisers’s Ginkgo Bioworks DNA Stock Holding History

PharVision Advisers’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,177
Closed -$192K – 759
2025
Q3 		$192K Buy
+13,177
New +$158K 0.11% 526

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PharVision Advisers's DNA Position: Q4 2025 in Review

PharVision Advisers sold out of Ginkgo Bioworks (DNA) in Q4 2025, closing a stake of 13,177 shares — an estimated $192K sold.

PharVision Advisers first reported a position in DNA in Q3 2025 and held it in 1 quarter. The position peaked at $192K in Q3 2025. 180 funds tracked by Wall St. Rank hold DNA as of Q4 2025.

  • PharVision Advisers reported no remaining Ginkgo Bioworks position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 13,177 Ginkgo Bioworks shares in Q4 2025, an estimated $192K.
  • PharVision Advisers first reported a position in Ginkgo Bioworks in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Ginkgo Bioworks position peaked at $192K in Q3 2025.
  • 180 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.